LMAT — LeMaitre Vascular, Inc.

Summary of LeMaitre Vascular Q2 2026 Earnings Call

1. Key Financial Results and Metrics

• Sales Growth: Q2 2026 sales grew 10% organically, with 7% from price increases and 3% from unit growth. Excluding catheters, organic growth was 12%.
• Net Income: Increased 24% year-over-year to $17.1 million.
• EPS: Fully diluted EPS rose 23% to $0.74.
• Operating Income: Reached a record $20.4 million, up 26%, resulting in a 29% operating margin.
• Gross Margin: Improved to 72.1%, a 210 basis point increase year-over-year.
• Cash Position: Ended Q2 with $376 million in cash and securities, generating $16 million from operations.

2. Strategic Updates and Business Highlights

• Product Performance: Artegraft sales grew 34%, becoming the largest product line. International sales increased significantly, with approvals in Vietnam, Morocco, and Turkey.
• Infrastructure Expansion: Ongoing investments in warehouses and sales force expansion, with plans to increase sales reps from 163 to 170-180 by year-end.
• RFA Growth: Revenues from allografts grew 17% in Q2, with plans for further expansion in Europe and other regions.
• Relocalization Initiative: A strategic focus on regional warehouses to improve logistics and reduce shipping costs, enhancing gross margins in Europe.

3. Forward Guidance and Outlook

• Full Year Guidance: Updated revenue guidance to $276.3 million, reflecting an 11% organic growth rate. EPS guidance raised to $2.89, indicating a 21% increase from the previous year.
• Challenges Ahead: Anticipated headwinds from currency fluctuations, export delays due to geopolitical issues, and supply constraints affecting cardiac allografts.

4. Bad News, Challenges, or Points of Concern

• Catheter Sales Decline: Catheter sales fell 11% due to a prior year’s overstocking from a recall, impacting overall growth metrics.
• Geopolitical Risks: Ongoing conflict in the Middle East is delaying export revenues, with significant orders unable to ship.
• Supply Constraints: Issues with cardiac allografts supply are expected to slow growth, despite a strong performance in Q2.
• Regulatory Hurdles: The FDA may require a clinical trial for the Quick Stick project, potentially delaying its market entry.

5. Notable Q&A Insights

• Resource Allocation for Quick Stick: Management is evaluating how to allocate resources for the Quick Stick project, acknowledging the need for a more R&D-focused approach.
• RFA Supply Constraints: Management is actively working to resolve supply issues, with plans to centralize processing in Burlington, Massachusetts.
• Geographical Performance: The Americas showed softer growth compared to Europe and Asia, primarily due to the catheter issue and procedural volume dynamics.
• Relocalization Benefits: The initiative is expected to enhance margins significantly, with shipping costs reduced by localizing operations closer to customers.

Overall, while LeMaitre Vascular demonstrated strong financial performance in Q2 2026, challenges related to geopolitical risks, supply constraints, and regulatory hurdles could impact future growth. The company is strategically investing in infrastructure and product development to position itself for long-term success.